Brokerages Anticipate Iradimed Corp (IRMD) to Announce $0.06 Earnings Per Share
Shares of Iradimed Corp (NASDAQ:IRMD) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Analysts have set a 1-year consensus target price of $16.00 for the company and are anticipating that the company will post $0.06 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Iradimed an industry rank of 163 out of 265 based on the ratings given to related companies.
A number of equities analysts recently commented on the company. Roth Capital assumed coverage on Iradimed in a report on Tuesday, October 31st. They set a “buy” rating and a $16.00 price target for the company. Credit Suisse Group initiated coverage on Iradimed in a report on Monday, November 27th. They set a “buy” rating and a $19.00 price objective for the company. Zacks Investment Research cut Iradimed from a “buy” rating to a “hold” rating in a report on Wednesday, December 20th. Finally, ValuEngine upgraded Iradimed from a “sell” rating to a “hold” rating in a report on Friday, October 6th.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IRMD. Ameriprise Financial Inc. acquired a new stake in shares of Iradimed in the second quarter valued at approximately $2,954,000. Citigroup Inc. raised its position in shares of Iradimed by 50.8% in the second quarter. Citigroup Inc. now owns 16,082 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 5,418 shares in the last quarter. Menta Capital LLC raised its position in shares of Iradimed by 5.7% in the second quarter. Menta Capital LLC now owns 70,476 shares of the medical equipment provider’s stock valued at $606,000 after buying an additional 3,823 shares in the last quarter. Neuberger Berman Group LLC raised its position in Iradimed by 23.3% during the second quarter. Neuberger Berman Group LLC now owns 18,500 shares of the medical equipment provider’s stock valued at $159,000 after purchasing an additional 3,500 shares in the last quarter. Finally, Connors Investor Services Inc. raised its position in Iradimed by 10.0% during the second quarter. Connors Investor Services Inc. now owns 33,000 shares of the medical equipment provider’s stock valued at $284,000 after purchasing an additional 3,000 shares in the last quarter. Institutional investors own 13.83% of the company’s stock.
Iradimed (NASDAQ IRMD) traded down $0.25 during trading on Wednesday, reaching $15.25. The company had a trading volume of 23,100 shares, compared to its average volume of 31,770. Iradimed has a fifty-two week low of $7.85 and a fifty-two week high of $15.85. The company has a market capitalization of $163.61, a PE ratio of 117.32 and a beta of 1.62.
Iradimed (NASDAQ:IRMD) last posted its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.35. Iradimed had a return on equity of 4.58% and a net margin of 6.51%. The business had revenue of $5.69 million during the quarter, compared to analysts’ expectations of $5.60 million. During the same quarter last year, the company posted $0.14 earnings per share. Iradimed’s quarterly revenue was down 25.9% on a year-over-year basis. research analysts expect that Iradimed will post 0.05 EPS for the current year.
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.